Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Asian Patients.

< BACK TO ARCHIVE


Papers: 19 Jan 2019 - 25 Jan 2019


Human Studies, Pharmacology/Drug Development


2019 Sep


J Diabetes Investig


http://www.ncbi.nlm.nih.gov/pubmed/30672128?dopt=Abstract


10


5

Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Asian Patients.

Authors

Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Asian Patients.
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S
J Diabetes Investig. 2019 Sep; 10(5):1299-1306.
PMID: 30672128.

Abstract

This study evaluated the efficacy and safety of mirogabalin, a novel, potent, selective ligand of the α δ subunit of voltage-dependent Ca channels, for the treatment of diabetic peripheral neuropathic pain (DPNP).
Read This Paper